Side effects and complication of stereotactic body radiation therapy for the treatment of residual hepatocellular carcinoma after chemoembolization

  • Đồng Đức Hoàng Trường Đại học Y Dược Thái Nguyên
  • Mai Hồng Bàng Bệnh viện Trung ương Quân đội 108
  • Thái Doãn Kỳ Bệnh viện Trung ương Quân đội 108
  • Nguyễn Tiến Thịnh Bệnh viện Trung ương Quân đội 108
  • Bùi Quang Biểu Bệnh viện Trung ương Quân đội 108
  • Nguyễn Đình Châu Bệnh viện Trung ương Quân đội 108

Main Article Content

Keywords

Hepatocellular carcinoma, stereotactic body radiation therapy, transarterial chemoembolization, complication

Abstract

Objective: To evaluate the safety of Stereotactic Body Radiation Therapy (SBRT) in the treatment of residual hepatocellular carcinoma after Transarterial Chemoembolization (TACE). Subject and method: This was prospective, controlled intervention study on 42 patients with hepatocellular carcinoma (HCC) treated with SBRT and 38 patients treated with TACE using DC Beads. Evaluation of complications after SBRT according to CTCAE V5.0. Result: Early side effects in group I patients were mainly fatigue (23.8%), group II mainly abdominal pain (47.4%), significant difference, p<0.05. Early complications in group I were acute hepatitis (4.8%), dermatitis (4.8%) which was not significantly different from group II (0%), p>0.05. Long-term complications in group I: Acute hepatitis (2.4%), pleural effusion (7.1%), dermatitis (2.4%) had no significant difference compared with group II: Acute hepatitis (0%), pleural effusion (2.6%), dermatitis (0%), p>0.05. There were no technique-related deaths in both groups. Conclusion: SBRT is a safe, uncomplicated treatment for patients with residual HCC after chemoembolization.

Article Details

References

1. Sapir E, Tao Y, Schipper MJ et al (2018) Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 100(1): 122-130.
2. Zeng ZC, Seong J, Yoon SM et al (2017) Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th asia-pacific primary liver cancer expert meeting. Liver Cancer 6(4): 264-274.
3. Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice Guidance by the American association for the study of liver diseases. Hepatology 68(2): 723-750.
4. U.S. Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 50 MedDRA MSSO.
5. Jacob R, Turley F, Redden DT et al (2015) Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3cm. HPB (Oxford) 17(2): 140-149.
6. Su TS, Lu HZ, Cheng T et al (2016) Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma > 5cm. BMC Cancer 16(1): 834.
7. Yao E, Chen J, Zhao X et al (2018) Efficacy of stereotactic body radiotherapy for recurrent or residual hepatocellular carcinoma after transcatheter arterial chemoembolization. Biomed Res Int 2018: 5481909.
8. Nagata Y (2015) Stereotactic body radiation therapy: Principles and practices springer Japan, Tokyo. 5: 177-188. https://doi.org/10.1007/978-4-431-54883-6.

Article Sidebar

PDF (Tiếng Việt)
Published
Jun 24, 2022
DOI: https://doi.org/10.52389/ydls.v17i4.1227
Issue
Volume 17 - No 4/2022
Section
Articles
How to Cite
Hoàng Đồng Đức, BàngM. H., KỳT. D., ThịnhN. T., BiểuB. Q., & ChâuN. Đình. (2022). Side effects and complication of stereotactic body radiation therapy for the treatment of residual hepatocellular carcinoma after chemoembolization. Tạp Chí Y Dược lâm sàng 108, 17(4). https://doi.org/10.52389/ydls.v17i4.1227